Methods: Through our multi-disciplinary team of vaccine and communications experts, we developed evidence-based information summaries on all vaccines recommended for routine use in the United States and each disease preventable by vaccination. We developed answers to frequently asked questions about vaccines and vaccination. Through our technology partner, we developed ReadyVax in a manner to provide clear and easy access to all of this information. Information is presented through expandable fields in four core screens (Vaccines, Diseases, Common Questions, and Resources). ReadyVax was deployed for use on iOS devices. Information complexity is tailored for different user types, including healthcare providers and patients/parents. As new information is updated into ReadyVax and accessed, it is stored on the user’s device, allowing access even when there is no network connectivity.
Results: ReadyVax was made available in the Apple App Store on January 12, 2015. By May 27, 2015, ReadyVax has been downloaded by 1,123 unique users, who have spent an average of one minute thirteen second perusing information in the app. There have been 3,628 unique screen views, an average of 2.6 screens/user session. ReadyVax has been downloaded by users in 57 different countries; most users (61.5%) are from the United States.
Conclusion: ReadyVax presents an opportunity to provide evidence-based information about vaccines and vaccination for routine use. We are continuing outreach efforts to public health partners to facilitate dissemination of ReadyVax. Continued use of ReadyVax can establish it as a trusted source of information, increasing the likelihood that in the event of a public health emergency, ReadyVax will serve as the main source of information dissemination with regard to vaccines in the emergency.
D. Salmon, None
E. Whitney, None
S. Omer, None